These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28002067)

  • 1. New mouse models provide insights into how to design a more effective HIV vaccine.
    Harper KN
    AIDS; 2017 Jan; 31(3):N3-N4. PubMed ID: 28002067
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune Correlate-Guided HIV Vaccine Design.
    Alter G; Barouch D
    Cell Host Microbe; 2018 Jul; 24(1):25-33. PubMed ID: 30001521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV neutralizing antibodies: clinical correlates and implications for vaccines.
    Doria-Rose NA
    J Infect Dis; 2010 Apr; 201(7):981-3. PubMed ID: 20170372
    [No Abstract]   [Full Text] [Related]  

  • 4. The 2017 Keystone Symposium on HIV Vaccines.
    Cottrell CA; Ward AB
    Hum Vaccin Immunother; 2017 Oct; 13(10):2348-2351. PubMed ID: 28786733
    [No Abstract]   [Full Text] [Related]  

  • 5. In pursuit of an HIV vaccine: an interview with Andrew McMichael.
    McMichael AJ
    BMC Biol; 2013 May; 11():60. PubMed ID: 23692824
    [No Abstract]   [Full Text] [Related]  

  • 6. Infectious disease. An enterprising time for HIV vaccine research.
    Cohen J
    Science; 2012 Sep; 337(6101):1446. PubMed ID: 22997300
    [No Abstract]   [Full Text] [Related]  

  • 7. The RV144 Thai HIV vaccine trial.
    Plotkin SA
    Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337
    [No Abstract]   [Full Text] [Related]  

  • 8. Remodeling of dynamic structures of HIV-1 envelope proteins leads to synthetic antigen molecules inducing neutralizing antibodies.
    Nakahara T; Nomura W; Ohba K; Ohya A; Tanaka T; Hashimoto C; Narumi T; Murakami T; Yamamoto N; Tamamura H
    Bioconjug Chem; 2010 Apr; 21(4):709-14. PubMed ID: 20359196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Blueprint for HIV Vaccine Discovery.
    Burton DR; Ahmed R; Barouch DH; Butera ST; Crotty S; Godzik A; Kaufmann DE; McElrath MJ; Nussenzweig MC; Pulendran B; Scanlan CN; Schief WR; Silvestri G; Streeck H; Walker BD; Walker LM; Ward AB; Wilson IA; Wyatt R
    Cell Host Microbe; 2012 Oct; 12(4):396-407. PubMed ID: 23084910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV neutralizing antibodies reignite interest in vaccine.
    Waltz E
    Nat Biotechnol; 2012 Mar; 30(3):204-5. PubMed ID: 22398603
    [No Abstract]   [Full Text] [Related]  

  • 11. PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.
    Fauci AS; Marston HD
    Science; 2015 Jul; 349(6246):386-7. PubMed ID: 26206922
    [No Abstract]   [Full Text] [Related]  

  • 12. [The new vaccine challenges of "humanization" of HIV].
    Nau JY
    Rev Med Suisse; 2013 Aug; 9(394):1490-1. PubMed ID: 24024395
    [No Abstract]   [Full Text] [Related]  

  • 13. AIDS research. Novel antibody response may explain HIV vaccine success.
    Cohen J
    Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV/AIDS: vaccines and alternate strategies for treatment and prevention.
    Voronin Y; Phogat S
    Ann N Y Acad Sci; 2010 Sep; 1205 Suppl 1():E1-9. PubMed ID: 20860672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV vaccine design: the neutralizing antibody conundrum.
    Stamatatos L
    Curr Opin Immunol; 2012 Jun; 24(3):316-23. PubMed ID: 22595693
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV Vaccines: One Step Closer.
    Low MSY; Tarlinton D
    Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RV144: old vs. new.
    Weiner DB
    Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335
    [No Abstract]   [Full Text] [Related]  

  • 19. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
    Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.